Standardised Genetic Profiling of Subjects Belonging to the Italian Multicenter Registry of Prospective Surveillance of Subjects at Genetic Risk of Pancreatic Cancer

Associazione Italiana per lo Studio del Pancreas1 site in 1 country3,000 target enrollmentDecember 20, 2022

ConditionsCandidates for Hereditary Pancreatic Cancer Testing

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Candidates for Hereditary Pancreatic Cancer Testing
Sponsor: Associazione Italiana per lo Studio del Pancreas
Enrollment: 3000
Locations: 1
Primary Endpoint: Presence - absence of predisposing mutations
Status: Recruiting
Last Updated: 3 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The goal of the PROPH-ITA Study is to perform genetic testing in family members of pancreatic cancer patients who may have a genetic predisposition. The subjects belong to the Italian Registry of Families At Risk of Pancreatic Cancer (IRFARPC, #NCT04095195). This investigational study will assess the genetic background of subjects with familiarity with pancreatic cancer only.

Participants may accept to undergo genetic testing as part of the IRFARPC registry, through a saliva-swab-based 41-gene panel test.

Up to 3,000 participants will be enrolled in this study.

Registry

clinicaltrials.gov

Start Date

December 20, 2022

End Date

December 20, 2028

Last Updated

3 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Associazione Italiana per lo Studio del Pancreas

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Being enrolled on the IRFARPC registry
•Having familiarity for pancreatic cancer (according to the IRFARPC criteria, Capurso et al. Dig Liv Dis, 2020)
•Willingness to participate in saliva-swab-based genetic testing